Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management.
Cognitive dysfunction is a common occurrence among patients with small-cell lung cancer, with prevalence rates ranging anywhere from 15% to 90%. Although prophylactic cranial irradiation has been described as one culprit to explain these cognitive deficits, other causes also have been implicated. This review provides a summary of the factors that may contribute to cognitive decline in this group of patients and comments upon how cognitive dysfunction or the risk for it might influence patient management.
Kanard
Anne
A
Department of Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Frytak
Stephen
S
Jatoi
Aminah
A
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D020274:Autoimmune Diseases of the Nervous System / Q000139:chemically induced / Q000503:physiopathology / Q000628:therapy; D001932:Brain Neoplasms / Q000453:epidemiology / Q000503:physiopathology / Q000556:secondary / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000453:epidemiology / Q000523:psychology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002945:Cisplatin / Q000627:therapeutic use; D003072:Cognition Disorders / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D016371:Cranial Irradiation; D019468:Disease Management; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000453:epidemiology / Q000523:psychology* / Q000628:therapy; D013404:Suggestion
D000970:Antineoplastic Agents; D002945:Cisplatin